NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $26.36 +0.19 (+0.73%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Zai Lab Stock (NASDAQ:ZLAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zai Lab alerts:Sign Up Key Stats Today's Range$25.59▼$26.5450-Day Range$16.25▼$26.3652-Week Range$13.48▼$31.22Volume967,921 shsAverage Volume636,551 shsMarket Capitalization$2.63 billionP/E RatioN/ADividend YieldN/APrice Target$56.21Consensus RatingBuy Company OverviewZai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.Read More… This man predicted today’s most valuable companies more than a decade ago. (Ad)How could it be that one analyst called the rise of Apple, Microsoft, Nvidia, and many of today’s best performing stocks more than a decade ago? Some might say it was luck… Others will say he was in the right place at the right time. But looking back, this analyst has made some incredible calls over his career… In fact, right now, he’s the #1 ranked stock picker in North America… To earn that title he’s beat out more than 16,000 stock market professionals. So how does one man accomplish all that? If you were to ask him, he’d give the credit to his stock rating system…. A system that has a history of predicting which stocks could soon rise by 100% or more…Check it out, just follow this link and enter your email address. Zai Lab Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks61st Percentile Overall ScoreZLAB MarketRank™: Zai Lab scored higher than 61% of companies evaluated by MarketBeat, and ranked 487th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingZai Lab has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageZai Lab has only been the subject of 1 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zai Lab are expected to grow in the coming year, from ($2.95) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.88% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Zai Lab has recently decreased by 10.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.88% of the outstanding shares of Zai Lab have been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Zai Lab has recently decreased by 10.33%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.95 News SentimentZai Lab has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zai Lab this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ZLAB on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zai Lab to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $72,548.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Email Address ZLAB Stock News HeadlinesStrong Buy Rating for Zai Lab: Outperforming Vyvgart Sales and Promising Global Pipeline Fuel OptimismOctober 14, 2024 | markets.businessinsider.comZai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024October 9, 2024 | businesswire.comThis man beat out 16,000 stock pickers to earn the #1 spotThere are very few people in this world who are considered “the best” in their field. There are guys like Michael Jordan who is considered the best basketball player of all time… Or Warren Buffet who is considered the best Investor of all time… But we’ve just met a man who might be the best stock picker of all time… Right now, as we speak, he is currently ranked the #1 stock picker in North America.October 18, 2024 | DTI (Ad)Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Time to Sell?October 8, 2024 | americanbankingnews.comZai Lab (NASDAQ:ZLAB) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comZai Lab's Growth Strategy And China's Policy Reforms Set Path For Profitability By 2025September 25, 2024 | seekingalpha.comBuy Rating Affirmed for Zai Lab on Robust Drug Sales Growth and Strong Market PositionSeptember 13, 2024 | markets.businessinsider.comZai Lab Limited (ZLAB): Top ADR Stock According to Hedge FundsAugust 29, 2024 | insidermonkey.comSee More Headlines ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $27.33 at the start of the year. Since then, ZLAB stock has decreased by 3.5% and is now trading at $26.36. View the best growth stocks for 2024 here. How were Zai Lab's earnings last quarter? Zai Lab Limited (NASDAQ:ZLAB) posted its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.16. The business earned $100.50 million during the quarter, compared to analyst estimates of $94.46 million. Zai Lab had a negative net margin of 92.44% and a negative trailing twelve-month return on equity of 37.96%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Meta Platforms (META), Advanced Micro Devices (AMD), Baidu (BIDU) and Home Depot (HD). Company Calendar Last Earnings8/06/2024Today10/17/2024Next Earnings (Confirmed)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZLAB CUSIPN/A CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees2,175Year FoundedN/APrice Target and Rating Average Stock Price Target$56.21 High Stock Price Target$73.34 Low Stock Price Target$38.00 Potential Upside/Downside+113.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-334,620,000.00 Net Margins-92.44% Pretax Margin-92.44% Return on Equity-37.96% Return on Assets-29.42% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.29 Sales & Book Value Annual Sales$322.71 million Price / Sales8.14 Cash FlowN/A Price / Cash FlowN/A Book Value$8.05 per share Price / Book3.27Miscellaneous Outstanding Shares99,609,000Free Float85,783,000Market Cap$2.63 billion OptionableOptionable Beta1.08 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:ZLAB) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.